• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral Anticoagulation for Atrial Fibrillation After TAVR: Is Vitamin K Antagonist Still the Primary Option?

作者信息

Van Belle Eric, Delhaye Cedric, Vincent Flavien

机构信息

Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, CHU Lille, Institut Cœur Poumon, Cardiology, Inserm, U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille, France.

出版信息

JACC Adv. 2023 Mar 31;2(2):100278. doi: 10.1016/j.jacadv.2023.100278. eCollection 2023 Mar.

DOI:10.1016/j.jacadv.2023.100278
PMID:38938293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11198499/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c636/11198499/076753b15b7e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c636/11198499/076753b15b7e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c636/11198499/076753b15b7e/fx1.jpg

相似文献

1
Oral Anticoagulation for Atrial Fibrillation After TAVR: Is Vitamin K Antagonist Still the Primary Option?经导管主动脉瓣置换术后房颤的口服抗凝治疗：维生素K拮抗剂仍是主要选择吗？
JACC Adv. 2023 Mar 31;2(2):100278. doi: 10.1016/j.jacadv.2023.100278. eCollection 2023 Mar.
2
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.TAVR术后艾多沙班与维生素K拮抗剂用于心房颤动的比较
N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28.
3
Use of Direct Oral Anticoagulant and Outcomes in Patients With Atrial Fibrillation after Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry.经导管主动脉瓣置换术后合并心房颤动患者使用直接口服抗凝药物的效果：STS/ACC TVT 注册研究的结果。
J Am Heart Assoc. 2022 Jan 4;11(1):e023561. doi: 10.1161/JAHA.121.023561. Epub 2021 Dec 31.
4
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
5
A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation.经导管主动脉瓣置换术后合并心房颤动患者中新型口服抗凝剂与维生素 K 拮抗剂的系统评价和荟萃分析。
Eur J Clin Pharmacol. 2022 Oct;78(10):1589-1600. doi: 10.1007/s00228-022-03371-6. Epub 2022 Aug 9.
6
Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation.非维生素K拮抗剂类抗凝剂的引入显著提高了老年房颤住院患者的抗凝率。
Drugs Aging. 2018 Sep;35(9):859-869. doi: 10.1007/s40266-018-0571-1.
7
TAVR Patients Requiring Anticoagulation: Direct Oral Anticoagulant or Vitamin K Antagonist?经导管主动脉瓣置换术（TAVR）患者需要抗凝：直接口服抗凝剂还是维生素 K 拮抗剂？
JACC Cardiovasc Interv. 2021 Aug 9;14(15):1704-1713. doi: 10.1016/j.jcin.2021.05.025. Epub 2021 Jul 14.
8
Direct oral anticoagulants or vitamin K antagonists after TAVR: A systematic review and meta-analysis.经导管主动脉瓣置换术（TAVR）后直接口服抗凝剂或维生素 K 拮抗剂：系统评价和荟萃分析。
Int J Cardiol. 2022 Oct 15;365:123-130. doi: 10.1016/j.ijcard.2022.07.039. Epub 2022 Jul 25.
9
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.“真实世界”的心房颤动抗栓治疗：EORP-AF 初步调查。
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
10
Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.经导管主动脉瓣置换术后接受依度沙班或维生素K拮抗剂治疗的心房颤动患者的治疗满意度和便利性：ENVISAGE-TAVI AF试验的事后分析
Am J Cardiol. 2023 Dec 15;209:212-219. doi: 10.1016/j.amjcard.2023.09.091. Epub 2023 Oct 14.

本文引用的文献

1
Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy.经导管主动脉瓣置换术后的阿哌沙班与瓣叶血栓：ATLANTIS-4D-CT 随机临床试验的子研究。
JACC Cardiovasc Interv. 2022 Sep 26;15(18):1794-1804. doi: 10.1016/j.jcin.2022.07.014. Epub 2022 Aug 31.
2
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.利伐沙班在风湿性心脏病相关心房颤动中的应用。
N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28.
3
Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort.
经导管主动脉瓣置换术中的脑微出血：一项前瞻性磁共振成像队列研究。
Circulation. 2022 Aug 2;146(5):383-397. doi: 10.1161/CIRCULATIONAHA.121.057145. Epub 2022 Jun 20.
4
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.阿哌沙班与经导管主动脉瓣置换术后标准治疗的比较：ATLANTIS 试验。
Eur Heart J. 2022 Aug 1;43(29):2783-2797. doi: 10.1093/eurheartj/ehac242.
5
2021 ESC/EACTS Guidelines for the management of valvular heart disease.2021年欧洲心脏病学会/欧洲心胸外科学会瓣膜性心脏病管理指南。
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
6
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.TAVR术后艾多沙班与维生素K拮抗剂用于心房颤动的比较
N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28.
7
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.ENGAGE AF-TIMI 48 试验中 8040 名女性与 13065 名男性房颤患者使用依度沙班的疗效和安全性结局比较。
Circulation. 2021 Feb 16;143(7):673-684. doi: 10.1161/CIRCULATIONAHA.120.052216. Epub 2021 Feb 15.
8
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020美国心脏病学会/美国心脏协会瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2021 Feb 2;77(4):e25-e197. doi: 10.1016/j.jacc.2020.11.018. Epub 2020 Dec 17.
9
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
10
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.经导管主动脉瓣置换术后联合或不联合氯吡格雷的抗凝治疗。
N Engl J Med. 2020 Apr 30;382(18):1696-1707. doi: 10.1056/NEJMoa1915152. Epub 2020 Mar 29.